Stonepine Capital Management LLC Purchases New Shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Stonepine Capital Management LLC purchased a new position in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 160,000 shares of the company's stock, valued at approximately $570,000. Stonepine Capital Management LLC owned 0.18% of Aquestive Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of the stock. New York State Common Retirement Fund grew its holdings in shares of Aquestive Therapeutics by 713.3% during the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock valued at $43,000 after purchasing an additional 10,700 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Aquestive Therapeutics during the fourth quarter worth about $44,000. PKS Advisory Services LLC bought a new stake in shares of Aquestive Therapeutics during the fourth quarter worth about $63,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Aquestive Therapeutics during the fourth quarter worth about $69,000. Finally, ProShare Advisors LLC grew its holdings in shares of Aquestive Therapeutics by 79.8% during the fourth quarter. ProShare Advisors LLC now owns 25,232 shares of the company's stock worth $90,000 after purchasing an additional 11,200 shares during the last quarter. Institutional investors own 32.45% of the company's stock.

Analyst Ratings Changes

Several brokerages recently commented on AQST. Raymond James set a $7.00 target price on Aquestive Therapeutics in a report on Friday, March 7th. Lake Street Capital dropped their price target on Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Friday, March 7th. Alliance Global Partners reissued a "buy" rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Finally, HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research note on Thursday, May 15th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $10.67.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST traded down $0.12 during trading on Wednesday, reaching $2.27. 1,287,178 shares of the stock were exchanged, compared to its average volume of 1,515,139. Aquestive Therapeutics, Inc. has a 1-year low of $2.12 and a 1-year high of $5.80. The stock has a fifty day moving average of $2.73 and a two-hundred day moving average of $3.31. The firm has a market cap of $225.47 million, a price-to-earnings ratio of -5.04 and a beta of 2.02.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The firm had revenue of $8.72 million during the quarter, compared to the consensus estimate of $12.23 million. Sell-side analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.